Justin Strote, MD
Interventional Cardiology · Fort Collins, CONPI 1255388955
Payments from drug & device makers
Across 432 payments — averaging $6520.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2.4M
- Abbott$307K
- W. L. Gore & Associates, Inc.$139K
- Boston Scientific$854
- Medtronic$779
- Abiomed$570
- plus $206 from 4 others
What the payments were for
- Consulting fees$9,82840%
- Travel & lodging$7,09829%
- Food & beverage$7,45531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 256 | $2,367,843 |
| Abbott | 81 | $307,062 |
| W. L. Gore & Associates, Inc. | 53 | $139,400 |
| Boston Scientific | 26 | $854 |
| Medtronic | 8 | $779 |
| Abiomed | 3 | $570 |
| Shockwave Medical, Inc | 2 | $158 |
| Asahi Intecc USA, Inc. | 1 | $26 |
| Cook Medical LLC | 1 | $19 |
| Z-medica, LLC | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,816,714 in reported general payments places this provider in the 95th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 180 | $268,213 |
| JardianceEmpagliflozin | 94 | $143,788 |
| XareltoRivaroxaban | 58 | $89,149 |
| Repatha SureclickEvolocumab | 81 | $77,897 |
| EntrestoSacubitril/Valsartan | 26 | $42,067 |
| Praluent PenAlirocumab | 43 | $39,992 |
| FarxigaDapagliflozin Propanediol | 29 | $34,911 |
| VascepaIcosapent Ethyl | 12 | $11,042 |
| Icosapent Ethyl | 12 | $5,306 |
| Atorvastatin Calcium | 445 | $5,066 |
| Ezetimibe | 179 | $4,194 |
| Metoprolol Succinate | 275 | $4,064 |
| Rosuvastatin Calcium | 303 | $3,170 |
| Losartan Potassium | 306 | $3,032 |
| Nebivolol Hcl | 37 | $2,264 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Fort Collins
- John OldemeyerFort Collins$2.7M
- Philip DattiloFort Collins$110K
- Anthony DoingFort Collins$51K
- Roger AshmoreFort Collins$14K
- Ehrin ArmstrongEnglewood$2.6M
- Ira DauberLittleton$2.6M
- Gareth MorganAurora$1.3M
- Connie HessAurora$919K
- Joseph BurchenalLittleton$631K
- Lee MacdonaldLittleton$627K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.